Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Swiss Exchange  >  Roche Holding Ltd.    ROG   CH0012032048

ROCHE HOLDING LTD. (ROG)
Mes dernières consult.
Most popular
  Report  
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsofficial PublicationsSector newsTweets

Roche Holding Ltd. : Roche purchases shares in tender offer for Anadys Pharmaceuticals

share with twitter share with LinkedIn share with facebook
share via e-mail
0
11/23/2011 | 07:15am CEST

Basel, 23 November 2011

Roche purchases shares in tender offer for Anadys Pharmaceuticals

Roche (SWX: ROG.VX; RO.S; OTCQX; RHHBY) today announced that its wholly owned subsidiary Bryce Acquisition Corporation has accepted for payment all shares validly tendered pursuant to its tender offer for all outstanding shares of common stock of Anadys Pharmaceuticals, Inc. (NASDAQ: ANDS) at $3.70 per share in cash.

As of the expiration of the tender offer, a total of approximately 54,532,568 shares of Anadys common stock were tendered and not withdrawn (including approximately 2,345,764  shares tendered by delivery of notices of guaranteed delivery), representing approximately 94% of Anadys's outstanding shares.

Roche intends to complete the acquisition of Anadys through a short-form merger without a vote or meeting of Anadys's shareholders. In the merger, all shares of Anadys not owned by Anadys, Roche or their respective wholly owned subsidiaries (other than shares as to which appraisal rights are validly exercised) will be converted into the right to receive the same cash consideration per share as was paid in the tender offer.

About Roche

Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world's largest biotech company with truly differentiated medicines in oncology, virology, inflammation, metabolism and CNS. Roche is also the world leader in in-vitro diagnostics, tissue-based cancer diagnostics and a pioneer in diabetes management. Roche's personalised healthcare strategy aims at providing medicines and diagnostic tools that enable tangible improvements in the health, quality of life and survival of patients. In 2010, Roche had over 80,000 employees worldwide and invested over 9 billion Swiss francs in R&D. The Group posted sales of 47.5 billion Swiss francs. Genentech, United States, is a wholly owned member of the Roche Group. Roche has a majority stake in Chugai Pharmaceutical Co., Ltd., Japan. For more information: www.roche.com.

Cautionary Statement Regarding Forward-Looking Statements

Some of the statements contained in this press release are forward-looking statements, including statements regarding the expected consummation of the acquisition, which involves a number of risks and uncertainties including the satisfaction of closing conditions for the acquisition such as regulatory approval for the transaction, the tender of a majority of the outstanding shares of common stock of Anadys and the possibility that the transaction will not be completed. These statements are based on our current expectations, assumptions, estimates and projections about our business and our industry, and involve known and unknown risks, uncertainties and other factors that may cause our or our industry's results, levels of activity, performance or achievements to be materially different from any future statements. We generally identify these statements by words or phrases such as "believe," "anticipate," "expect," "intend," "plan," "will," "may," "should," "estimate," "predict," "potential," "continue," or the negative of such terms or other similar expressions. If underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results and the timing of events may differ materially from the results discussed in the forward-looking statements, and you should not place undue reliance on these statements. The information contained in this press release is as of November 23, 2011. We disclaim any intent or obligation to update any forward-looking statements as a result of developments occurring after the period covered by this report or otherwise.

Important Additional Information

This press release is for informational purposes only and does not constitute an offer to purchase or a solicitation of an offer to sell Anadys common stock. The tender offer is being made pursuant to a tender offer statement on Schedule TO (including the Offer to Purchase, Letter of Transmittal and other related tender offer materials) filed by Roche with the Securities and Exchange Commission (the "SEC") on October 25, 2011 [and subsequently amended]. These materials, as they may be further amended from time to time, contain important information, including the terms and conditions of the offer, that should be read carefully before any decision is made with respect to the tender offer. Investors and Anadys's stockholders can obtain a free copy of these materials and other documents filed by Roche with the SEC at the website maintained by the SEC at www.sec.gov. The tender offer materials may also be obtained for free by contacting the information agent for the tender offer, Mackenzie Partners at (212) 929-5500 (call collect) or (800) 322-2885 (toll-free) (USA).

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on ROCHE HOLDING LTD.
05/25AstraZeneca cancer drug hits second goal by extending survival
RE
05/21Roche Presents Positive Results From Hemlibra Trials
DJ
05/21GENENTECH : ’s HEMLIBRA (emicizumab-kxwh) Reduced Treated Bleeds by 96 Per..
BU
05/18AstraZeneca insists future is bright after big Crestor sales hit
RE
05/16Reducing Use of Roche Drug for Breast Cancer Didn't Hurt Efficacy, Study Says
DJ
05/16ROCHE : Phase III IMpower150 Study Showed Genentech’s TECENTRIQ and Avasti..
BU
05/16ROCHE : Follow-up Phase III Data Showed Genentech’s Alecensa Helped People..
BU
05/15Roche's Actemra Gets FDA Nod for Pediatric Subcutaneous Use
DJ
05/14ROCHE : FDA Approves Subcutaneous Formulation of Actemra for Use in Active Polya..
BU
05/14GENENTECH : to Present New Phase III Data for HEMLIBRA (emicizumab-kxwh) in Peop..
BU
More news
News from SeekingAlpha
05/25Roche Holding (RHHBY) Virtual Pipeline Event From WFH 2018 World Congress - S.. 
05/24AbbVie's Imbruvica + Roche's Gazyva successful in late-stage leukemia study 
05/23Roche Holding ADR (RHHBY) Presents At 2018 UBS Global Healthcare Conference -.. 
05/223Pea Is A Payment Processor With >40% Organic Growth Selling For Half Of Peer.. 
05/22Fibrogen Makes A Strong Case As An Acquisition Target After Latest Lung Fibro.. 
Financials ( CHF)
Sales 2018 55 741 M
EBIT 2018 18 660 M
Net income 2018 12 050 M
Debt 2018 4 564 M
Yield 2018 3,98%
P/E ratio 2018 15,07
P/E ratio 2019 14,52
EV / Sales 2018 3,45x
EV / Sales 2019 3,25x
Capitalization 188 B
Chart ROCHE HOLDING LTD.
Duration : Period :
Roche Holding Ltd. Technical Analysis Chart | ROG | CH0012032048 | 4-Traders
Technical analysis trends ROCHE HOLDING LTD.
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 29
Average target price 262  CHF
Spread / Average Target 20%
EPS Revisions
Managers
NameTitle
Severin Schwan Chief Executive Officer & Executive Director
Christoph Franz Chairman
Alan Hippe Chief Financial & Information Technology Officer
John Irving Bell Non-Executive Director
Andreas Oeri Independent Non-Executive Director
Sector and Competitors
1st jan.Capitalization (M$)
ROCHE HOLDING LTD.-9.17%189 708
JOHNSON & JOHNSON-11.45%325 801
PFIZER-0.91%208 713
NOVARTIS-8.30%194 397
MERCK AND COMPANY5.01%158 970
AMGEN2.33%117 942